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Novel Urinary Peptidomic Classiﬁer Predicts Incident Heart Failure
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Background-—Detection of preclinical cardiac dysfunction and prognosis of left ventricular heart failure (HF) would allow targeted
intervention, and appears to be the most promising approach in its management. Novel biomarker panels may support this
approach and provide new insights into the pathophysiology.
Methods and Results-—A retrospective comparison of urinary proteomic proﬁles generated by mass spectrometric analysis from
49 HF patients, 36 patients who progressed to HF within 2.61.6 years, and 192 sex- and age-matched controls who did not
progress to HF enabled identiﬁcation of 96 potentially HF-speciﬁc peptide biomarkers. Based on these 96 peptides, the classiﬁer
called Heart Failure Predictor (HFP) was established by support vector machine modeling. The incremental prognostic value of HFP
was subsequently evaluated in urine samples from 175 individuals with asymptomatic diastolic dysfunction from an independent
population cohort. Within 4.8 years, 17 of these individuals progressed to overt HF. The area under receiver-operating
characteristic curve was 0.70 (95% CI, 0.56–0.82); P=0.0047 for HFP and 0.57 (0.42–0.72; P=0.62) for N-terminal pro b-type
natriuretic peptide. Hazard ratios were 1.63 (CI, 1.04–2.55; P=0.032) per 1-SD increment in HFP and 0.70 (CI, 0.35–1.41; P=0.32)
for a doubling of the logarithmically transformed N-terminal pro b-type natriuretic peptide.
Conclusions-—HFP is a novel biomarker derived from the urinary proteome and might serve as a sensitive tool to improve risk
stratiﬁcation, patient management, and understanding of the pathophysiology of HF. ( J Am Heart Assoc. 2017;6:e005432. DOI:
10.1161/JAHA.116.005432.)
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L eft ventricular (LV) heart failure (HF) is a clinicalsyndrome caused by adverse LV structural or functional
alterations resulting in impaired ventricular ﬁlling and/or
ejection and thus in the disability of the heart to pump a
sufﬁcient amount of blood to meet the metabolic needs of the
body.1,2 HF represents an enormous public health and
socioeconomic burden.1,2 Because of etiological diversity, it
is difﬁcult to clearly identify all contributing factors in a
clinical setting and to depict the complex pathophysiology by
single biomarkers. Difﬁculties thus arise in diagnosis, risk
stratiﬁcation, and management of HF patients.2 A position
paper of the American Heart Association supported research
into proteomics as applied to cardiovascular health and
disease.3 In line with this recommendation, we developed
multidimensional proteomic biomarkers characterizing dis-
tinct molecular manifestations of LV dysfunction that may
provide additional diagnostic and prognostic value and
identify new targets of treatment. We already identiﬁed
speciﬁc peptide biomarker patterns helping in the diagnosis of
coronary artery disease,4 and asymptomatic LV dias-
tolic5,6and systolic7 dysfunction. The present study aimed to
extend the ﬁndings5–7 of these case–control5,7 and cross-
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sectional6 studies and to investigate whether the urinary
proteomic signature might predict progression from asymp-
tomatic LV dysfunction to overt symptomatic HF.
Methods
Study Participants
For discovery of the urinary biomarkers, we investigated 95
patients enrolled in the GS (Generation Scotland: Scottish
Family Health Study),8 who had either HF at baseline (n=57)
or progressed to HF during follow-up (n=38) and 192 sex- and
age-matched healthy controls selected from the same cohort.
For validation, we studied 175 patients with asymptomatic
diastolic LV dysfunction at baseline enrolled in the FLEMENGHO
(Flemish Study on Environment, Genes and Health Out-
comes5,6), of whom over a 4.8-year period 17 developed HF
during follow-up. The diagnosis of HF was ascertained against
the records held by general practitioners or hospitals in the
catchment area of the FLEMENGHO study.9 Both GS (ethical
approval registration number, 10/S1402/20) and FLEMEN-
GHO (ML4804) complied with the Helsinki declaration for
research in humans10 and received ethical approval. Permis-
sion for health record linkage in GS was obtained from the
Privacy Advisory Committee of NHS National Services Scot-
land. The FLEMENGHO database is registered with the Belgian
Privacy Commission (www.privacycommission.be). All partic-
ipants gave informed written consent.
Deﬁnition of LV Dysfunction
In the GS study,8 HF was an ICD-coded admission to the
hospital for symptomatic HF. In FLEMENGHO,5,6 the diagnosis
of subclinical LV diastolic dysfunction relied on echocardio-
graphy. To ascertain the absence of symptoms, participants
completed the London School of Hygiene questionnaires on
cardiovascular and respiratory symptoms.11 As described
elsewhere,12 guideline-driven echocardiographic criteria to
stage patients with advanced diastolic LV dysfunction leave a
large proportion of people unclassiﬁed in population studies.
We therefore developed age-speciﬁc criteria in a healthy
reference sample drawn from FLEMENGHO12 and replicated
these criteria in an independent European population study.13
Diastolic LV dysfunction included12,13: (1) patients with an
abnormally low age-speciﬁc transmitral E/A ratio indicative of
impaired relaxation, but without evidence of increased LV
ﬁlling pressures (E/e0 ≤8.5); (2) patients with a mildly-to-
moderately elevated LV ﬁlling pressure (E/e0 >8.5) and an E/
A ratio within the normal age-speciﬁc range; and (3) patients
with an elevated E/e0 ratio and an abnormally low age-speciﬁc
E/A ratio (combined dysfunction).
Proteomic Urine Sample Analysis
Sample preparation and capillary electrophoresis–mass
spectrometry analysis
For proteomic analysis, a 0.7-mL aliquot of stored urine was
thawed immediately before use and diluted with 0.7 mL of
2 mol/L urea, and 10 mmol/L NH4OH containing 0.02%
sodium dodecyl sulphate. To remove higher molecular mass
proteins, such as albumin and immunoglobulins, the sample
was ultraﬁltered using Centrisart ultracentrifugation ﬁlter
devices (20 kDa MWCO; Sartorius, G€ottingen, Germany) at
3000 relative centrifugal force units until 1.1 mL of ﬁltrate
was obtained. This ﬁltrate was then applied onto a PD-10
desalting column (GE Healthcare, Uppsala, Sweden) equili-
brated in 0.01% NH4OH in HPLC-grade in H2O (Carl Roth
GmbH, Karlsruhe, Germany) to decrease matrix effects by
removing urea, electrolytes, salts, and to enrich polypeptides.
Finally, all samples were lyophilized, stored at 4°C, and
suspended in HPLC-grade H2O shortly before capillary
electrophoresis–mass spectrometry (CE-MS) analyses.14
CE-MS analyses were performed using a P/ACE MDQ
capillary electrophoresis system (Beckman Coulter, Fullerton,
CA) on-line coupled to a micrOTOF MS (Bruker Daltonics,
Bremen, Germany).14,15 The electrospray ionization device
(Agilent Technologies, Palo Alto, CA) was grounded, and the
ion spray interface potential was set between 4 and
4.5 kV. Data acquisition and MS acquisition methods were
automatically controlled by the CE via contact-close-relays.
Spectra were accumulated every 3 s, over a mass-to-charge
ratio (m/z) ranging from 350 to 3000.
Quality control
Accuracy, precision, selectivity, sensitivity, reproducibility
(Figure 1), and stability of the CE-MS have been previously
Clinical Perspective
What Is New?
• We identiﬁed a novel multidimensional urinary biomarker
consisting of 96 peptide fragments and named it heart
failure predictor.
• Heart failure predictor predicts progression from asymp-
tomatic left ventricular dysfunction to overt heart failure and
is more accurate than a research-optimized N-terminal pro
b-type natriuretic peptide assay.
What Are the Clinical Implications?
• Heart failure predictor might serve as a tool to improve risk
stratiﬁcation, patient management, and understanding the
pathophysiology of heart failure.
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published.14,16 Quality control involves daily CE-MS runs of
human urine standards.16 CE has a high reproducibility with at
least 70% of peptide recovered compared with only 43% by
liquid chromatography. To prevent variability because of carry-
over effects from 1 to the next run, capillaries are recondi-
tioned between runs (eg, 1 mol/L NaOH). Figure 1 shows
proteome coverage of 6 CE-MS runs of human urine
standards. The coefﬁcient of variance estimated from over
600 urine samples collected once daily for over 3 years was
5.8%.17
Mass spectrometric data processing
Mass spectral peaks representing identical molecules at
different charge states were deconvoluted into single masses,
using MosaiquesVisu software.18 Only signals with z of more
than 1 observed in a minimum of 3 consecutive spectra with a
signal-to-noise ratio of at least 4 were considered. Reference
signals of 1770 urinary polypeptides were used for CE-time
calibration by locally weighted regression. For normalization
of analytical and urine dilution variances, signal intensities
were normalized relative to 29 “housekeeping” peptides.19,20
The obtained peak lists characterize each polypeptide by its
molecular mass, normalized CE migration time, and normal-
ized signal intensity. All detected peptides were deposited,
matched, and annotated in a Microsoft SQL database,
allowing further statistical analysis.21 For clustering, peptides
in different samples were considered identical, if mass
deviation was <50 ppm. CE migration time was controlled
to be below 0.35 minutes after calibration.
Sequencing of polypeptides
HF biomarkers were in silico assigned to the previously
sequenced peptides from Human Urinary Proteome Database,
version 2.0.22 Peptides from this database were sequenced,
A B C
D E F
Figure 1. Proteome coverage of 6 CE-MS runs (A through F) of human urine standards. The molecular mass on a logarithmic scale
(0.8–20 kDa on the y-axis) was plotted against the normalized CE migration time (15–45 minutes on the x-axis). Peak height and color
represent average signal intensity. The human urine standard is a urine sample from a randomly selected healthy person that is used for quality
control.16 CE-MS indicates capillary electrophoresis–mass spectrometry.
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as described elsewhere.23,24 Brieﬂy, urinary peptides were
fragmented using different tandem mass spectrometric
techniques with a prior separation step with CE or HPLC.
Fragmentation spectra were matched to the protein
sequences from up-to-date public databases (IPI, NCBI
Reference Sequence Database and Uniprot), using MS/MS
search engines MASCOT (Matrix Sciences Ltd., London, UK)
and OMSSA (National Center for Biotechnology Information,
Bethesda, MD). In matching, we accounted for urinary
proteins posttranslational modiﬁcations, such as hydroxyla-
tion of lysine and proline, and speciﬁc MS characteristics.
Peptide sequences from liquid chromatography–MS analyses
were veriﬁed by the comparison of experimental and
theoretical CE migration time, which is dependent on the
number of basic and neutral polar amino acids.
Identiﬁed HF-speciﬁc urinary peptides were combined into
a single multidimensional classiﬁer called Heart Failure
Predictor (HFP), using the support vector machine-based
MosaCluster software, version 1.7.0.25 MosaCluster calcu-
lates classiﬁcation scores based on the amplitudes of the
selected biomarkers. Classiﬁcation is performed by determin-
ing the Euclidian distance (deﬁned as the support-vector
machine classiﬁcation score) of the vector to a maximal
margin hyperplane. The parameters for derivation of the HFP
classiﬁer were 6.4 for C, 0.008192 for gamma, and 0.001 for
epsilon. In sensitivity analyses, we forced sex and age into the
computations of the classiﬁcation scores.
Other Measurements
Hypertension was a blood pressure of at least 140 mm Hg
systolic or 90 mm Hg diastolic or use of antihypertensive
drugs. Venous blood samples were drawn after at least
6 hours of fasting for measurement of plasma glucose and
serum total and high-density lipoprotein cholesterol and
serum creatinine. We derived the estimated glomerular
Table 1. Baseline Characteristics of Cases and Controls Nested in the GS
Characteristic HF at Baseline Incident HF Healthy Controls
Number 57 38 192
Number of subjects, %
Women 18 (31.6) 12 (31.6) 61 (31.3)
Hypertension 46 (80.7) 26 (68.6) 157 (81.8)
Diabetes mellitus 9 (15.8) 3 (7.9) 8 (4.2)
Obesity 23 (41.1) 10 (26.3) 42 (22.0)
Mean (SD) of characteristic
Age, y 6910* 6411 649
Body mass index, kg/m2 295* 285 275
Waist-to-hip ratio 0.940.08* 0.910.07 0.910.09
Blood pressure, mm Hg
Systolic pressure 13623 14321 14117
Diastolic pressure 7813* 8112* 8210
Heart rate, beats per minute 6812 7014 6711
Biochemical data
Serum creatinine, lmol/L 9428* 8519* 8013
eGFR, mL/min per 1.73 m2 7422* 8017* 8515
Total cholesterol, mmol/L 4.31.0* 4.91.4* 5.21.1
HDL cholesterol, mmol/L 1.20.4* 1.30.4* 1.40.4
Plasma glucose, mmol/L 5.82.2* 5.21.6* 5.11.3
NT-proBNP, pg/mL 278 (93–774)* 132 (69–242)* 48 (32–72)
Values are mean (SD) or geometric mean (interquartile range). Hypertension was an ofﬁce blood pressure of ≥140 mm Hg systolic, ≥90 mm Hg diastolic, or use of antihypertensive
drugs. Diabetes mellitus was a self-reported diagnosis, a fasting glucose level of at least 7 mmol/L, or use of antidiabetic agents. Obesity was a body mass index of ≥30 kg/m2. For
NT-proBNP, values are geometric mean (interquartile range). eGFR indicates estimated glomerular ﬁltration rate; HDL, high-density lipoprotein; HF, heart failure; NT-proBNP, N-terminal
pro-b-type natriuretic peptide.
*Indicates a difference (P≤0.05) between cases and controls.
DOI: 10.1161/JAHA.116.005432 Journal of the American Heart Association 4
Heart Failure and the Urinary Peptidome Zhang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
ugust 10, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
ﬁltration rate from serum creatinine by the Modiﬁcation of
Diet in Renal Disease formula.26 Diabetes mellitus was a self-
reported diagnosis, a fasting glucose level of at least 7 mmol/
L, or use of antidiabetic agents.27 In the GS study,8 N-terminal
proatrial natriuretic peptide (NT-proBNP) was measured using
an automated ELISA assay (Roche Diagnostics, Basel,
Switzerland) with an interassay coefﬁcient of variation of
<3%. The lower limit of detection was 5 pg of NT-proBNP per
mL. In the FLEMENGHO study,12,13 NT-proBNP was measured
in plasma by a competitive enzyme immunoassay for research
use (Biomedica Gruppe, Vienna, Austria).28 The interassay and
intra-assay variations were lower than 15%. The lower
detection limit was 5 pmol of NT-proBNP/L. The standard
range provided by the manufacturer of the enzyme
immunoassay is from 0 to 1000 pmol/L (median,
208 pmol/L; 95% percentile, 300 pmol/L).
Statistical Analysis
We compared means and proportions characterizing the study
participants at baseline by Student t test and Fisher exact
test, respectively. We compared urinary peptide levels with a
detectable signal in at least 30% of participants by the
nonparametric Wilcoxon rank sum test. Unadjusted P values
were calculated using the normal approximation of the
Wilcoxon test statistic. In the GS study, we applied the
Benjamini-Hochberg approach with the false discovery rate
set at 5%.29 We used Cox regression to compute hazard ratios
Figure 2. Flow chart illustrating the peptides retained in the generation of HFP. HFP indicates Heart
Failure Predictor.
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Table 2. Sequenced Peptides Included in the Heart Failure-Speciﬁc Peptide Panel in the GS Cohort
ID Sequence Protein Name Accession Number BAS INC Overlap
107929 DAaHKSEVAHRFKDLGEENFKALVL Serum albumin P02768 +28.1 +44.5
2505 SpGEAGRpG Collagen a-1(I) chain P02452 2.2 1.3 2
2659 DDGEAGKpG Collagen a-1(I) chain P02452 2.1 1.2 2
5675 DGKTGPpGPA Collagen a-1(I) chain P02452 2.1 1.2
14906 DGRpGPpGPpG Collagen a-1(I) chain P02452 2.7 1.4 2
16779 ApGDRGEpGPP Collagen a-1(I) chain P02452 2.8 +1.3
17694 ApGDRGEpGpP Collagen a-1(I) chain P02452 2.8 1.3 2
21365 PpGEAGKpGEQG Collagen a-1(I) chain P02452 +1.8 1.0 2
23697 DDGEAGKpGRpG Collagen a-1(I) chain P02452 2.1 1.2 1
28561 SpGPDGKTGPpGPA Collagen a-1(I) chain P02452 2.9 1.5 1,2
30575 SpGSpGPDGKTGPp Collagen a-1(I) chain P02452 3.3 1.2
32171 ApGDRGEpGPpGPA Collagen a-1(I) chain P02452 1.5 1.2 1,2
35339 ApGDRGEpGPpGPAG Collagen a-1(I) chain P02452 1.4 1.1 1,2
42594 VGPpGpPGPPGPPGPPS Collagen a-1(I) chain P02452 1.8 1.2
43442 VGPpGPpGPpGPPGPPS Collagen a-1(I) chain P02452 1.4 1.1
50638 PpGPpGKNGDDGEAGKP Collagen a-1(I) chain P02452 2.1 +1.1
51175 EGSpGRDGSpGAKGDRG Collagen a-1(I) chain P02452 2.3 +1.1
51875 VGPpGPpGPpGPPGPPSAG Collagen a-1(I) chain P02452 +1.6 +1.1
62504 TGPIGPpGPAGApGDKGESGP Collagen a-1(I) chain P02452 +2.1 +1.2
63209 EGSpGRDGSpGAKGDRGET Collagen a-1(I) chain P02452 2.0 1.1 2
65257 SGEpGApGSKGDTGAKGEpGP Collagen a-1(I) chain P02452 +1.7 +3.2 2
72896 SGEpGApGSKGDTGAKGEpGPVG Collagen a-1(I) chain P02452 +1.2 +1.4
75846 GPpGEAGKpGEQGVpGDLGApGP Collagen a-1(I) chain P02452 +1.2 +1.3
77018 DGQPGAKGEpGDAGAKGDAGPPGp Collagen a-1(I) chain P02452 +1.2 +1.4
78073 AEGSpGRDGSpGAKGDRGETGPA Collagen a-1(I) chain P02452 1.1 2.1
81457 IGPpGPAGApGDKGESGPSGPAGPTG Collagen a-1(I) chain P02452 1.1 1.8
82234 IGPpGPAGApGDkGESGPSGPAGPTG Collagen a-1(I) chain P02452 1.2 2.6
87460 KGNSGEPGApGSKGDTGAKGEPGPVG Collagen a-1(I) chain P02452 +1.5 +1.9
99808 LTGPIGPPGpAGApGDKGESGPSGPAGPTG Collagen a-1(I) chain P02452 1.2 1.2
118163 LTGSpGSpGpDGKTGPPGPAGQDGRPGPpGppG Collagen a-1(I) chain P02452 1.1 1.5
36769 DGPpGRDGQpGHKG Collagen a-2(I) chain P08123 1.2 2.1
48093 GpAGPRGERGPpGESGA Collagen a-2(I) chain P08123 +1.2 +2.0 2
110240 LKGQpGApGVKGEpGApGENGTPGQTGARG Collagen a-2(I) chain P08123 +7.7 +2.2
114086 TGEVGAVGPpGFAGEKGPSGEAGTAGPpGTpGP Collagen a-2(I) chain P08123 +1.3 +2.0
18988 DGESGRpGRpG Collagen a-1(III) chain P02461 1.2 3.0
28747 SpGERGETGPpGP Collagen a-1(III) chain P02461 +1.1 +1.4 1
30699 DGApGKNGERGGpG Collagen a-1(III) chain P02461 1.0 2.4 2
36784 DGVPGKDGPRGPTGP Collagen a-1(III) chain P02461 +1.0 +2.0 2
38798 GLpGTGGPpGENGKpG Collagen a-1(III) chain P02461 1.1 2.1 2
49295 ApGGKGDAGApGERGPpG Collagen a-1(III) chain P02461 +1.2 +1.8
61304 GLpGTGGPpGENGKPGEPGp Collagen a-1(III) chain P02461 +1.5 +3.6 2
61945 GLpGTGGPpGENGKpGEPGp Collagen a-1(III) chain P02461 +1.6 +2.6 2
Continued
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and to determine clinical characteristics relevant for progres-
sion to overt HF. We identiﬁed covariables to be retained by a
backward elimination with the P value set at 0.1. Variables
with physiological relevance that were not retained by the
stepdown procedure were combined in a propensity score30
derived by regressing HFP on covariables, including sex, body
mass index, mean arterial pressure, heart rate, LV mass index,
treatment with inhibitors of the renin system, and use of
b-blockers. To account for the small sample size in the
replication sample (FLEMENGHO5,6), we applied Firth
regression.31 In FLEMENGHO participants,5,6 we evaluated
the discriminatory performance of HFP by constructing the
receiver operating characteristic curve and calculating the
area under the receiver operating characteristic curve.
Results
Design of HFP in the GS Study
Cases were 57 patients with overt HF (ICD10 code, I50.1)
present at baseline and 38 patients who over a 5-year follow-
up period progressed to symptomatic HF requiring hospital-
ization (median time to event, 2.9 years). Among cases with
incident HF, 19 (50%) had elevated levels of NT-proBNP
(>125 pg/mL) at baseline. Controls were 192 sex- and age-
matched healthy individuals with normal NT-proBNP level
(Table 1).
Impaired renal function is a potential confounder in urinary
biomarker discovery.32 We therefore excluded the 10 patients
with an estimated glomerular ﬁltration rate of <45 mL/min
per 1.73 m2 (stage 3B according to the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative guide-
line [www.kidney.org]) from biomarker discovery, leaving 49
with overt HF at baseline and 36 with incident HF. The total
number of detected peptide fragments was 5616, but only
1380 (24.6%) with a signal in at least 30% of study
participants were analyzed. Of these 1380 peptides (Fig-
ure 2), 722 were not sequenced and 658 were sequenced.
The sequenced peptides enabled identiﬁcation of 157 parent
proteins. Comparison of cases and controls with the false
discovery rate set at 5% identiﬁed 96 potential peptide
biomarkers, of which 59 were characterized by sequence and
posttranslational modiﬁcation (Table 2). The majority of the
sequenced peptides originated from the extracellular matrix
and were fragments of collagen I (n=33), III (n=10), as well as
collagen IV, VII, and IX (each n=1). Other peptides originated
Table 2. Continued
ID Sequence Protein Name Accession Number BAS INC Overlap
64887 GApGApGGKGDAGApGERGPpG Collagen a-1(III) chain P02461 +1.3 +2.4
107460 KNGETGPQGPPGPTGPGGDKGDTGPpGpQG Collagen a-1(III) chain P02461 1.2 1.7 1
84484 pGFPGAQGEPGSQGEpGDpGLpGP Collagen a-2(IV) chain P08572 +1.6 +2.8
30500 GApGLAGpAGpQGpS Collagen a-1(VII) chain Q02388–2 +1.7 +2.1
86029 PpGppGPpGVPGSDGIDGDNGPPGK Collagen a-2(IX) chain H0Y409 +1.3 +2.0
129940 DVGSYQEKVDVVLGPIQLQTPPRREEEPR Deleted in malignant brain tumors 1 protein Q9UGM3 +1.4 +2.0
98089 DEAGSEADHEGTHSTKRGHAKSRP Fibrinogen a chain P02671 +1.6 +2.4 1
103912 DEAGSEADHEGTHSTKRGHAKSRPV Fibrinogen a chain P02671 +1.4 +1.9
17968 DGGGSPKGDVDP Sodium/potassium–transporting ATPase subunit c P54710 1.2 1.4 2
13747 ATKTVGSDTF Kininogen-1 P01042–2 +1.1 2.8
67263 GSGGSSYGSGGGSYGSGGGGGGGRG Keratin; type II cytoskeletal 1 P04264 1.1 1.6
59368 FGASAGTGDLSDNHDIIS Vesicular integral–membrane protein VIP36 Q12907 +1.7 +3.0
73434 KDQGGYTmHQDQEGDTDAG Microtubule–associated protein s; MAPT P10636 1.3 1.7 1
87692 EDPQGDAAQKTDTSHHDQDHP Short peptide from AAT G3V387 1.3 2.1
73015 ELTETGVEAAAASAISVARTL Plasma protease C1 inhibitor P05155 +1.9 +5.7
111426 IPVKQADSGSSEEKQLYNKYPDAVAT Osteopontin P10451 +1.9 +1.5
118694 IPVKQADSGSSEEKQLYNKYPDAVATW Osteopontin P10451 +2.9 +7.1
The analysis of 49 cases with HF at baseline (BAS), 36 cases with incident HF (INC), and 192 controls identiﬁed 59 differentially excreted peptides that could be sequenced. The accession
number is the identiﬁer in the UniProtKB database (www.uniprot.org). BAS and INC are fold changes of amplitude comparing heart failure cases at baseline (BAS) and incident heart failure
at follow-up (INC) to normal controls, respectively. The differential excretion was computed as (amplitude cases9frequency)/(amplitude control9frequency) or as (amplitude
controls9frequency)/(amplitude cases9frequency) for upregulated (+) and downregulated () proteins in cases vs controls, respectively. Amplitude refers to the average mass
spectrometric signal and frequency to the number of individuals with a detectable signal. Overlap refers to the peptide fragments also included in the previously published HF1
(1; reference 5) and HF patients with reduced ejection fraction (2; reference 7) classiﬁers. HF indicates heart failure.
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from a-1-antitrypsin, ﬁbrinogen a (n=2), kininogen-1, micro-
tubule-associated protein s, osteopontin (n=2), plasma pro-
tease C1 inhibitor, and serum albumin (Table 2).
To reduce overﬁtting in the support vector machine
modeling, for the generation of a novel multidimensional
classiﬁer for HF, we included all available 95 cases, irrespec-
tive of their renal function. The resulting classiﬁer, HFP
(threshold level 0.22), allowed correct discrimination of 57
patients with HF at baseline and 38 patients with incident HF
versus 192 controls with 100% accuracy upon complete take-
1-out cross-validation. HFP had 11 (11.5%) peptide fragments
in common with the earlier published classiﬁers HF1 devel-
oped in hypertensive patients with asymptomatic LV diastolic
dysfunction5,6 and shared 22 (22.9%) peptides with HFrEF103
derived in HF patients with reduced ejection fraction.7
Twenty-two of these common peptides have a known
sequence (Table 2). Forcing sex and age into the computa-
tions of the classiﬁcation scores did not affect the perfor-
mance of HFP.
Replication of HFP in the FLEMENGHO Study
The prognostic utility of HFP was assessed in the independent
FLEMENGHO cohort by applying the classiﬁer onto the
proteome proﬁles of 175 individuals with asymptomatic LV
diastolic dysfunction but without previous coronary events
(Table 3). Median follow-up was 4.7 years (interquartile
range, 4.5–5.1; range, 1.1–8.4 years) in 158 patients who
did not progress to HF and 5.0 years (interquartile range, 4.4–
6.2; range, 3.4–7.2) in 17 patients who developed overt
diastolic HF (P=0.20). In stepdown Cox regression, age was
the only covariable retaining signiﬁcance. With adjustment for
age and the propensity score, the hazard ratio for HF
associated with HFP in Firth regression was 1.64 (CI, 1.05–
2.53; P=0.029) for a 1-SD increment. The corresponding
hazard ratio for logarithmically transformed NT-proBNP was
0.70 (CI, 0.36–1.38; P=0.31). In similarly adjusted models
including both biomarkers, the hazard ratios were 1.63 (CI,
1.04–2.55; P=0.032) for HFP and 0.70 (CI, 0.35–1.41;
P=0.32) for NT-proBNP.
The area under the receiver operating characteristic curve
for NT-proBNP was 0.57 (95% CI, 0.42–0.72; P=0.62). For
HFP, the area under the receiver operating characteristic
curve was 0.70 (CI, 0.56–0.82; P=0.0047; Figure 3). The
performance of the classiﬁer made up of only type I collagens
fragments (n=33) generated an area under the receiver
operating characteristic curve of 0.60 (CI, 0.44–0.76;
P=0.21).
Discussion
We identiﬁed urinary peptide biomarkers with prognostic
value for the progression from asymptomatic LV dysfunction
to overt HF. The ensuing multidimensional classiﬁer HFP
surpassed a research-optimized NT-proBNP assay in the
prediction of progression to symptomatic HF. NT-ProBNP, an
inactive fragment of the cleaved pro-BNP molecule, is the
guideline-endorsed state-of-the-art clinical marker to conﬁrm
HF diagnosis.33
From a mechanistic point of view, HFP extensively depicts
speciﬁc excretory molecular phenotypic alterations associ-
ated with progressive LV dysfunction. Fragments of ﬁbrillar
Table 3. Baseline Characteristics of Cases and Controls in
the FLEMENGHO Study
Characteristic Cases Controls
Number 17 158
Number of subjects, %
Women 11 (64.7) 90 (57.0)
Hypertension 13 (76.5) 128 (81.0)
Diabetes mellitus 3 (17.7) 13 (8.2)
Obesity 4 (23.5) 52 (32.9)
Mean (SD) of characteristic
Age, y 726* 6413
Body mass index, kg/m2 284 284
Waist-to-hip ratio 0.890.08 0.900.08
Blood pressure, mm Hg
Systolic pressure 14219 14319
Diastolic pressure 769* 8210
Heart rate, beats per minute 5511* 6311
Biochemical data
Serum creatinine, lmol/L 8519 8721
eGFR, mL/min per 1.73 m2 7116 7214
Total cholesterol, mmol/L 5.40.8 5.51.0
HDL cholesterol, mmol/L 1.50.3 1.40.3
Plasma glucose, mmol/L 5.61.9 5.21.1
NT-proBNP, pmol/L 269 (251–432) 245 (166–389)
Echocardiography data
LVEF, % 689 709
e0 peak, cm/s 7.51.7 7.71.9
E/e0 9.92.6 9.22.9
Values are mean (SD) or geometric mean (interquartile range). Hypertension was an
ofﬁce blood pressure of ≥140 mm Hg systolic, ≥90 mm Hg diastolic, or use of
antihypertensive drugs. Diabetes mellitus was a self-reported diagnosis, a fasting
glucose level of at least 7 mmol/L, or use of antidiabetic agents. Obesity was a body
mass index of ≥30 kg/m2. For NT-proBNP, values are geometric mean (interquartile
range). eGFR indicates estimated glomerular ﬁltration rate; FLEMENGHO, Flemish Study
on Environment, Genes and Health Outcomes; HDL, high-density lipoprotein; HF, heart
failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-b-type
natriuretic peptide.
*Indicates a difference (P≤0.05) between cases and controls.
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type I and III collagen, important components of the
myocardial extracellular matrix,34 predominantly make up
the proteomic urinary signature associated with HF. These
observations are in line with altered collagen synthesis,35
chemical/enzymatic cross-linking,36 and/or turnover by dif-
ferent proteases35,37 as the mechanisms underlying the
perturbed LV mechanics and geometry38,39 and progression
to HF.40 Renal dysfunction secondary to HF32 might also have
contributed to the urinary peptide excretion pattern as
captured by HFP.
In addition to collagens, the biomarker pattern included
peptide fragments from a-1-antitrypsin and osteopontin,
which showed an elevated differential excretion in cases
(Table 2). Levels of a-1-antitrypsin progressively increase
across the New York Heart Association classes of HF and
correlate with B-type natriuretic peptide.41 This might be a
compensatory mechanism for the loss of anti-protease
activity as a consequence of oxidative stress. The presence
of a kininogen-1 fragment in HFP indicated that alterations in
kininogen-1 and therefore kinins, its cleavage products, may
also be relevant for the diagnosis and prediction of HF. Kinins,
such as bradykinin (kallidin-I) and lysyl-bradykinin (kallidin-II),
are potent vasoactive and inﬂammatory peptides acting
through the formation of nitric oxide radicals and prostacy-
clin.42 Inhibition of kinin degradation by angiotensin-convert-
ing enzyme inhibitors increases LV ejection fraction and
decreases the LV end-diastolic volume,43 thereby underscor-
ing the relevance of kinins in the pathophysiology of HF.
Moreover, in line with the observed increased HF-related
excretion of osteopontin and altered excretion of collagen
type I and III, Lopez and coworkers demonstrated that
elevated expression of osteopontin in HF patients correlated
with collagen cross-linking lysyl oxidase and insoluble
collagen.44 Combined with NT-proBNP, osteopontin improves
the diagnosis of acute heart failure and reﬁnes risk
stratiﬁcation.45
Conclusions
HFP is a novel biomarker derived from the urinary proteome
and might serve as a tool to improve risk stratiﬁcation, patient
management, and understanding of the pathophysiology of
HF. While the prognostic utility of HFP has been validated in a
fully independent cohort, our study must be interpreted within
the context of its limitations. First, the number of patients
progressing to overt HF in the validation cohort was relatively
small (9.7%), thus limiting the statistical assessment of the
prognostic utility. However, we applied Firth regression as a
bias-corrected approach to conventional Cox regression.
Second, we derived HFP from peptides with a detectable
signal in at least 30% of study participants. Incomplete data
might be perceived as a weakness. However, ignoring
biomarkers with missing values wastes potentially important
information, explaining why in proteomic studies missing
values of 50% or more are commonly accepted without
consensus about the threshold to be applied. Moreover, the
30% threshold in this article is in keeping with our previously
published peer-reviewed research. Third, the fact that not all
identiﬁed polypeptides were sequenced impedes to some
extent the insight into the pathophysiological mechanisms
underlying HF. Finally, our current study cannot prove the
origin of the urinary collagen fragments. However, we are now
running proteomics on biopsies taken from explanted (dis-
eased) and implanted (healthy) hearts during cardiac trans-
plantation surgery in an attempt to prove that the urinary and
tissue proteomic signatures are similar (http://erc.europa.e
u/projects-and-results/erc-funded-projects/prophet). In spite
of these limitations, our study underscores the diagnostic and
prognostic power of a multidimensional biomarker approach.
Further studies are necessary to reach the high level of
evidence sufﬁcient to establish HFP as a clinically valuable
test.
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